Top 5 Duchenne Muscular Dystrophy Content of 2024
From imaging innovations to new treatment approvals, 2024 brought advancements in Duchenne muscular dystrophy care and research.
This year’s top stories on Duchenne muscular dystrophy (DMD) managed care included a novel imaging method for tracking disease progression, an
Here are AJMC.com’s 5 most-viewed DMD pieces of 2024. You can check out all our DMD coverage
5. Novel Imaging Algorithm Shows Promise in DMD Evaluation
A novel robust reference frequency method (RRFM) outperformed traditional imaging techniques in assessing ambulatory function progression in patients with DMD. Researchers found that RRFM-based ultrasound attenuation imaging significantly reduced measurement bias and offered superior diagnostic performance compared with other imaging methods, such as Nakagami and entropy analysis. With an area under the receiver operating characteristic curve of 0.92 in differentiating early and late ambulatory stages, RRFM showed potential as a noninvasive, reliable tool for managing DMD care.
4. Health State Utility Scores for DMD-Related Impairment Need to Better Reflect Patient Input
Research at the beginning of the year highlighted the need for patient-reported outcomes to better capture how DMD affects patients’ quality of life. Using tools like the Health Utilities Index and EQ-5D-5L, researchers found that health utility scores declined as disease severity increased, with nonambulatory patients reporting the lowest scores. The findings emphasize the unique insights patients can provide, which may not always align with caregiver assessments.
3. Cycling Training Shows Protective Effects on Gait, Balance in DMD
Cycling training demonstrated benefits for maintaining and improving balance and gait in children with DMD, outperforming traditional home-based exercise in enhancing antero-posterior balance. Both exercise approaches preserved key mobility parameters, which are vital for maintaining quality of life in this progressive condition. While the study was limited by its short duration and lack of follow-up, it highlights the potential of cycling as a targeted rehabilitation strategy for patients with DMD.
2. Givinostat Receives Full FDA Approval for Duchenne Muscular Dystrophy
In March, the FDA approved givinostat (Duvyzat) for boys aged 6 years and older with DMD, marking it as the first nonsteroidal therapy for the condition. A histone deacetylase inhibitor, givinostat has shown in clinical trials to improve functional outcomes like stair-climbing ability and delay fat infiltration in muscles when combined with corticosteroids. The approval followed positive results from the EPIDYS trial, which demonstrated reduced disease progression and manageable side effects.
1. Insurance Insights: Dr Jason Shafrin Estimates DMD Insurance Value
Jason Shafrin, PhD, joined an episode of Managed Care Cast to discuss
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Related Articles
- Promising Early Efgartigimod Response Data for Generalized Myasthenia Gravis
September 18th 2025
- Iron Dysregulation Linked to MS Progression, Review Finds
September 18th 2025
- Metabolic Issues More Common in Patients With HIV
September 18th 2025
- Barriers to Gender-Affirming Surgery Persist Despite High Satisfaction Rate
September 18th 2025